The Latest Breaking News from Madrigal Pharmaceuticals

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

As of Nov. 25, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

Madrigal said Wednesday it could win FDA approval for its nonalcoholic steatohepatitis treatment in March, and MDGL stock jumped.

Madrigal snagged a breakthrough therapy designation for its liver disease treatment on Tuesday and MDGL stock surged closer to a buy point.

  Madrigal Pharmaceuticals (NASDAQ:MDGL) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.